Literature DB >> 20812828

Watery eye following patent external DCR: an MR dacryocystography study.

Efstathios T Detorakis1, Eleni Drakonaki, Efrosini Papadaki, Ioannis G Pallikaris, Miltiadis K Tsilimbaris.   

Abstract

PURPOSE: To examine patients with persistent watery epiphora following patent external dacryocystorhinostomy (DCR) with magnetic resonance imaging dacryocystography (MR-DCG).
METHODS: Patients with unobstructed nasolacrimal irrigation following external DCR were included. Five patients with watery epiphora constituted the study group (SG). Five patients without epiphora constituted the control group (CG). All patients underwent MR-DCG following the instillation of artificial tears in the conjunctival fornix. The osteotomy site was identified in T1-weighted coronal images. Lacrimal flow was assessed with modified T2-weighted (True Fast Imaging Steady State Pulse, "TrueFISP") coronal images before and 10 min after repeated blinking. Signal intensities at three regions of interest (ROIs), corresponding to the eyeball (ROI-1), conjunctival sac (ROI-2), and anastomotic site (ROI-3) were measured.
RESULTS: Differences in the diameter of both osseous and soft tissue ostia between SG and CG were statistically not significant. A post-blink increase in signal intensity at ROI-3 was noted in both groups, whereas differences in signal intensity for ROI-1 and ROI-2 were statistically not significant. The post-blink signal intensity increase in ROI-3 was significantly more pronounced in the CG, compared with the SG.
CONCLUSIONS: The fact that signal intensity increase at ROI-3 was less pronounced in the SG, compared with CG, implies a compromised "lacrimal pump" mechanism in the former group. The methodology presented may be used for the evaluation of post-DCR epiphora.

Entities:  

Mesh:

Year:  2010        PMID: 20812828     DOI: 10.3109/01676831003660697

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  8 in total

Review 1.  [Significance of transcanalicular laser assisted dacryocystorhinostomy in modern lacrimal drainage surgery].

Authors:  K R Koch; H Kühner; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

Review 2.  [Minimally invasive bypass surgery for nasolacrimal duct obstruction : Transcanalicular laser-assisted dacryocystorhinostomy].

Authors:  K R Koch; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2017-05       Impact factor: 1.059

3.  The effectiveness of simultaneous medial spindle and/or lateral tarsal strip procedure in East Asian patients who need endonasal dacryocystorhinostomy.

Authors:  Hwa Lee; Jong-Suk Lee; Minwook Chang; Minsoo Park; Sehyun Baek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-22       Impact factor: 3.117

4.  Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction.

Authors:  Joel M Mor; Yongwei Guo; Konrad R Koch; Ludwig M Heindl
Journal:  J Vis Exp       Date:  2017-10-13       Impact factor: 1.355

5.  Transcanalicular laser dacryocystorhinostomy for acquired nasolacrimal duct obstruction: an audit of 104 patients.

Authors:  Joel M Mor; Mario Matthaei; Holger Schrumpf; Konrad R Koch; Edwin Bölke; Ludwig M Heindl
Journal:  Eur J Med Res       Date:  2018-11-16       Impact factor: 2.175

6.  The electromyographic analysis of orbicularis oculi muscle in epiphora.

Authors:  Titap Yazicioglu; Rahsan Inan; Anıl Agaçkesen; Murat Oklar; Saban Şimşek
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

Review 7.  Lacrimal outflow mechanisms and the role of scintigraphy: current trends.

Authors:  Efstathios T Detorakis; Athanassios Zissimopoulos; Konstantinos Ioannakis; Vassilios P Kozobolis
Journal:  World J Nucl Med       Date:  2014-01

8.  Cause and Management of Patients With Failed Endonasal Dacryocystorhinostomy.

Authors:  Ji Sun Baek; Seong Hun Jeong; Jung Hye Lee; Hye Sun Choi; Sung Joo Kim; Jae Woo Jang
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-07       Impact factor: 3.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.